This umbrella trial is designed to detect actionable oncogenic drivers in patients with suspected, resectable, early-stage NSCLC scheduled to undergo standard of care diagnostic biopsies to establish the diagnosis of lung cancer. Tumor samples are sent to next generation sequencing (NGS) for determining the presence of 11 oncogenic drivers (mutations in EGFR, BRAFV600E, MET exon 14, KRAS G12C, and HER2, rearrangements in ALK, RET, NTRK, and ROS1, and amplification of MET and HER2) in Clinical Laboratory Improvement Amendments (CLIA)-certified laboratories. Here, ERBB2 is linked to lung cancer.